Kornimate/medical-research-clean huggingface dataset:
evaluation of two different toothpastes for clinical management of extrinsic stains.

Conditions: Extrinsic Staining of Tooth - Medication

Summary: the aim of the study is to assess the efficacy of blanx black toothpaste against extrinsic stains of teeth. patients who sign the informed consent will participate to the study. at the baseline, the collection of plaque index, modified lobene index and bleeding index will be performed, giving the instruction for a proper home oral hygiene. professional supragingival and subgingival dental hygiene with piezoelectric will be performed. then, patients will be randomly divided into two groups: * trial group will use blanx black toothpaste (2 minutes brushing) twice a day for the all the study duration; * control group will use colgate sensation white toothpaste (2 minutes brushing) twice a day. patients will be reevaluated after 10 days, after 1 month and after 3 months, collecting again the indices and improving home oral care.

the aim of the study is to assess the efficacy of blanx black toothpaste against extrinsic stains of teeth. for this purpose, patients addressing to the dental hygiene unit that agree to participate to the study will be enrolled after signing the informed consent. at the baseline, the collection of plaque index, modified lobene index and bleeding index will be performed, giving the instruction for a proper home oral hygiene. professional supragingival and subgingival dental hygiene with piezoelectric will be performed. then, patients will be randomly divided into two groups: * trial group will use blanx black toothpaste (2 minutes brushing) twice a day for the all the study duration; * control group will use colgate sensation white toothpaste (2 minutes brushing) twice a day. patients will be reevaluated after 10 days, after 1 month and after 3 months. after the reinforcement of home oral hygiene, the above mentioned indices will be collected.

Eligibility criteria:
inclusion criteria: * age \> 18 years * presence of extrinsic stains * patients with high compliance exclusion criteria: * underage patients * patients suffering from neurological or psychiatric disorders * pregnant women * patients undergoing anticancer chemotherapy * patients with low compliance

Keywords: toothpaste extrinsic stains
effect of oral galactose on focal segmental glomerulosclerosis (fsgs) permeability factor

Conditions: Focal Segmental Glomerulosclerosis

Summary: this study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with resistant fsgs.

patients with resistant fsgs have persistent proteinuria and a high risk of progression to end stage kidney disease (eskd). a circulating factor that increases glomerular permeability to albumin (palb) has been detected in over 50% of these patients. while the molecular identity of the factor has not been fully established, in vitro studies and limited clinical experience suggest that galactose can reduce the level of the fsgs permeability factor. this study is a pilot study to determine if oral administration of galactose can lower the circulating level of the fsgs permeability factor. two groups of patients with biopsy proven primary fsgs who are resistant to steroids and one other immunosuppressive agents will be studied: l. fsgs, pre-eskd 2. fsgs, with eskd on renal replacement therapy the only eligibility factor is presence of the fsgs permeability factor. five patients will be included in each group. the experimental intervention is administration of galactose, orally, 0.2 g/kg body weight/dose twice daily. the duration of treatment will be 28 days,. patients will be seen on days 0, 14, and 28 of treatment. they will be seen at week 8, 16 and 24 after discontinuation of the galactose. physical examination and routine laboratory tests (smac, cbc, urine protein:creatinine ratio in an early morning sample) will be done at each visit. the fsgs permeability factor will be assayed at days 0 and 28 of treatment and 6 months after discontinuation of the galactose. the permeability factor will be tested in the laboratory of virginia savin md (medical college of wisconsin) using previously described methods. all other treatments will be unchanged during the 28 day oral galactose treatment period. the study will be analyzed based on the number of patients in whom the fsgs permeability factor is lowered to normal levels.

Eligibility criteria:
inclusion criteria: * primary fsgs * resistance to steroids and another immunosuppressive medication exclusion criteria: * secondary fsgs

Keywords: fsgs permeability factor galactose primary fsgs, resistant to immunosuppressive medication
fat-associated cardiovascular organ dysfunction

Conditions: Overweight; Obesity

Summary: this is an observational study of cardiovascular risk factors and arterial or cardiac function in subjects with overweight or obesity. subjects must be between 30 and 65 years of age, have a body mass index \>27.0 kg/m2 and free from known heart disease and digestive or psychiatric disorders. study aims include identifying sex-differences in traditional cardiovascular risk factors and structural and functional abnormalities in arteries and the heart in subjects with overweight or obesity, and how this is influenced by physical fitness.

fatcor is an observational study of women and men with overweight or obesity. in particular prevalences of conventional cardiovascular risk factors and subclinical arterial or cardiac dysfunction are explored. the study aims at identifying sex differences in presence and clustering of cardiovascular risk factors and presence of subclinical cardiovascular organ damage. the influence of physical fitness on these factors will also be assessed. all participants undergo extensive cardiovascular risk factor assessment including oral glucose tolerance test and ambulatory blood pressure recording. subclinical cardiovascular dysfunction is assessed by carotid and femoral vascular ultrasound, echocardiography and carotid-femoral pulse wave velocity using applanation tonometry. physical fitness is assessed from peak oxygen uptake during maximal exercise testing on a treadmill.

Eligibility criteria:
inclusion criteria: * body mass index \> 27.0 kg/m2 exclusion criteria: * known heart disease * digestive disorder * psychiatric disorder * unfamiliar with norwegian language
cladribine combined with g-csf and cytarabine as a salvage treatment in r/r all

Conditions: Acute Lymphoblastic Leukemia

Summary: to explore the efficiency and safety of clag regimen in r/r all

r/r acute lymphoblastic leukemia has poor response to second-line chemotherapy.here,we want to explore efficiency and safety of clag regimen in r/r all.

Eligibility criteria:
inclusion criteria: the patients meet the diagnostic criteria for relapsed/refractroy b-all. ecog score is 0-3. expecting life span is more than 6 weeks. exclusion criteria: patients are combined with severe organ dysfunction or organ failure: cardiac failure, liver and kidney insufficiency. patients are combined with severe infection or other complications that can not tolerate chemotherapy. patients are considered as other tumor progression. patients have used cladribine. pregnant and lactating women will not be included.
effect of myofascial release by foam rolling on back muscles endurance

Conditions: Back Injuries

Summary: this study evaluate the effect of the a low back self-application of myofascial release using a foam rolling on back muscles endurance measured by the biering-sorensen test.

self-myofascial release performed with a foam roller is an incoming technique what is very popular in sport. scientific literature currently suggests that the effects of self-myofascial release are mediated by the stimulation over neural and connective tissue. there is evidence that this stimulation could improve the maximum range of motion and decrease muscle soreness. nonetheless, there is few evidence about the effects of self-myofascial release on muscle endurance. given the increased use of autonomously (self-treatment) in the athlete population, this study aims to assess the effect of a low back short application (60 seconds) on the back extensor muscles endurance measured by the biering-sorensen test. with the obtained results we want to elaborate an evideced based recommendation about its use prior to physical activity or sports competition.

Eligibility criteria:
inclusion criteria: * basketball players, between 18-25 years who participate on a official league and do regular physical training (4 training sessions 1.5 hours each and a competitive session a week) * be able to read and understand the premises of the informed consent of the study. exclusion criteria: * to present some osteo-articular and / or muscle-tendon pathology that could be exacerbated by the implementation of the biering-sorensen test or by the intervention with foam compression.

Keywords: myofascial release back extensors endurance foam roller sport
a multicenter prospective non-interventional study assessing the management of canadian women with uterine fibroids

Conditions: Leiomyoma

Summary: this study will characterize the treatments and outcomes associated with different uterine fibroid treatments in canada, to understand patients' preferences and satisfaction with different medical and procedural interventions. the study will also assess the effectiveness of ulipristal acetate (fibristal®) in controlling bleeding, reducing fibroid volume and symptoms, and improvement in patient's quality of life.


Eligibility criteria:
inclusion criteria: -pre-menopausal adult women with confirmed diagnosis and symptoms associated with uterine fibroids who are initiating treatment. exclusion criteria: -significant pelvic pathology not associated with uterine fibroids.
desarda tissue technique vs lichtenstein technique for primary inguinal hernia repair

Conditions: Inguinal Hernia Unilateral; Complications of Surgical Procedures or Medical Care

Summary: this study aims to evaluate whether a surgical technique (desarda) is superior to the commonly used surgical technique (lichtenstein) in inguinal hernia repair concerning the occurrence of postoperative complications. the lichtenstein technique involves the use of a mesh, while the desarda technique does not.


Eligibility criteria:
inclusion criteria: * diagnosed with primary inguinal hernia. * body mass index below 31 * indication for inguinal hernia repair via anterior approach, either as outpatient surgery (cma) or elective admission. * legal capacity to provide informed consent. exclusion criteria: * patients with a weak, thin, or divided external oblique aponeurosis. * participants diagnosed with any of the following conditions: * ongoing oncological disease * cirrhotic patients classified as child b or higher * women who have previously undergone a cesarean section * cognitive or affective conditions that limit the ability to cooperate with the study procedures

Keywords: inguinal hernia lichtenstein technique desarda technique
comparison of three treatment in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: in this study, considering the importance of walking and balance functions in improving the quality of life and achieving independence in children with cerebral palsy, it was aimed to examine whether core stabilization exercises specifically designed for children with cerebral palsy have an impact on improving balance and walking functions as well as quality of life. additionally, the study sought to determine whether this approach has superiority over conventional balance exercises.

children with cerebral palsy included in the study were randomized into three groups using block randomization based on age, type of cerebral palsy and the gross motor function classification system (gmfcs). children with cerebral palsy aged 7-18 years were included. group 1 (study group, n=12) received neurodevelopmental therapy (ndt) combined with core stabilization exercises (cse). group 2 (study group, n=12) received ndt combined with balance exercises (be). the control group (n=12) received only ndt. treatments were conducted for 60 minutes per session, three times a week, over 8 weeks, for a total of 24 sessions, with an equal duration across groups. participants' balance was evaluated using the pediatric balance scale (pbs) and the sportkat 550® device. the trunk involvement scale (tis) was used to measure trunk impairment, the six-minute walk test (6mwt) to assess functional mobility and walking capacity and the pediatric outcome data collection instrument (podci) to evaluate quality of life. all assessments were performed by the same physiotherapist before and after treatment

Eligibility criteria:
inclusion criteria: * cases between the ages of 7-18 * cases with gmfcs level i and ii * cases diagnosed with hemiparetic and diparetic cp exclusion criteria: * cases with levels iii, iv and v according to gmfcs * having an intellectual disability that would prevent participation in assessment and exercise training * having had botulinum toxin (botox) type a application within the last 6 months * having undergone any surgical operation within the last 6 months * hearing and vision problems

Keywords: balance cerebral palsy core stabilization exercise neurodevelopmental therapy quality of life
the use of smart glasses for environmental controls

Conditions: Neurologic Disorder

Summary: environmental control systems are a type of assistive technology that can be controlled by a wide variety of different methods (e.g. switches) and can assist people with physical disabilities to control various electronic devices in the home. communication aids are designed to assist people who have difficulties speaking to communicate. both systems are designed to provide independence and potentially could have a positive effect on quality of life. the majority of communication aid and environmental control systems aimed at high end users require a screen to be mounted in front of the user. the limitations with this are that the user is only able to access their device when it has been suitably mounted in front of them. there are occasions when mounting devices in front of the user is difficult due to other considerations for example transfers in and out of a wheelchair. as smart glasses can potentially be worn at all times during the day this could provide an effective alternative solution. the purpose of this study is to explore with service users the usability and satisfaction provided by smart glasses when operating a communication aid/environmental control system. the study will achieve the above aim by undertaking a satisfaction questionnaire prior and post a 3 week trial of using smart glasses with their device. in addition an interview will be carried out with participants to explore the impact that smart glasses has had on the usability of their device. participants will be recruited by contacting eligible patients of the nhs lothian environmental control service and communication aid service. the end point of the study will be 8 months from the start date (allowing for follow up data to be collected for anyone recruited towards the end of the 6-month recruitment period).


Eligibility criteria:
inclusion criteria: * existing environmental control system user (age 18-80). * neurological condition. * cognitive ability to answer the questions and to give consent. * current environmental control system is compatible with smart glasses display. exclusion criteria: * current environmental control system or communication aid is not compatible with smart glasses display. * rapidly deteriorating condition

Keywords: environmental controls smart glasses activities of daily living self-help devices wearable technology
co2 laser in the treatment of the gsm - (genitourinary syndrome of menopause) genitourinary syndrome of menopause

Conditions: Menopause; Vaginal Atrophy; Urinary Incontinence

Summary: menopause is a woman's hormonal status one year after her ovulatory failure, when the decrease of circulating estrogen levels leads to a group of symptoms named genitourinary syndrome of menopause (gsm), such as: vaginal dryness, dyspareunia, dysuria, epithelial fragility with recurrent bleedings, loss of genital elasticity and ph alterations causing recurrent infections. the co2 laser is a fractional ablative source of light, capable of inducing neocollagenesis within the skin, reversing atrophies, increasing blood supply and reorganizing the architectural structure of the treated epithelium. recent studies in the laser field show great improvement of the sgm, with satisfying results in female's sexual disfunction. nevertheless, there is still a lack of studies that show, at the same time, the improvement in both patient's subjective reports and objective measurements, such as cytology, histology and immunohistochemistry. this study aims to thoroughly analyze the benefits of the co2 laser in the treatment of the gms, comparing the improvement found in questionnaires to the results of cytology, histology and immunohistochemistry for collagen i and iii from vaginal biopsies before and after the laser treatment. therefore, fourteen women after menopause complaining of symptoms of the gsm were selected from the ambulatory of the hospital universitário antônio pedro. the patients will be submitted to three co2 intravaginal laser (femilift®), with a 30-days interval between them. biopsies of the vaginal wall will be taken one month before the start and one month after the end of the laser sessions, and material will be sent to histology, cytology and immunohistochemistry analysis. results obtained will be compared to the patients' reports, in order to evaluate subjective and objective improvement due to the treatment.


Eligibility criteria:
inclusion criteria: * women from 40 to 70 years old; * post- menopausa (at least one year after cessation of periods); * experimenting any symptom related to the genitourinary syndrome of menopause (gsm), such as: vaginal dryness, dyspareunia, urinary incontinence, dysuria, recurrent urinary infections; * regular follow up in gynecologist, with recent normal pap smear. exclusion criteria: * the volunteers must not be under any treatment for this syndrome; * volunteers cannot be using hormones or any vaginal treatment; * volunteers cannot have previous history of vaginal / uterine cancer; * volunteers cannot have previous surgery for urinary incontinence; * uterine prolapse; * recent altered pap smear.

Keywords: menopause vaginal atrophy urinary incontinence co2 laser fractional laser dyspareunia vaginal dryness vaginal lubrication
feasibility study to assess the safety and functionality of the glusense continuous glucose monitor in diabetic patients

Conditions: Diabetes

Summary: currently marketed cgm sensors have an approved functional lifetime of up to 1 week. pre-clinical studies have demonstrated that glusense-ltone 2e3 sensors may be used to accurately monitor glucose levels for 30 days. the purpose of this study is to assess the safety and functionality of the device in human patients for consecutive 15 days. glusense-ltone 2e3 as long term cgm, will require less sensor replacements and calibration, meaning less patient interventions, and is therefore will be much more user friendly. moreover, glusense-ltone 2e3 shows potentially increased accuracy, especially in the critically important hypoglycemic range, meaning that better management of patient's condition may be attained.

glusense-ltone 2e3 is a continuous glucose monitoring (cgm) system. it is a semi-invasive, optical fiber-based device with a lifetime of up to one month. the purpose of this study is to assess the safety, accuracy, calibration requirements and effective lifetime of the device.

Eligibility criteria:
inclusion criteria: patients must meet all of the following inclusion criteria to be eligible for participation in this study: * male or female patients between 18 and 50 years of age * patients with type 1 diabetes mellitus. * the ability to read, understand and sign an informed consent form. written consent must be obtained prior to initiation of study procedures exclusion criteria: patients who meet any of the following exclusion criteria are not to be enrolled in this study: * clinical significant illness that can compromise patient's health during study such as: * significant current heart disease * significant liver or kidney disease * hiv infection * hepatitis b or hepatitis c infection * malignancy * major allergic skin disease including plaster allergies * significant allergic disorders * current or recent significant skin conditions (e.g. eczema, psoriasis,). * presence of skin markings/ abnormalities around implantation site that will interfere with the skin assessment e.g. tattoos, piercings, birthmark, sunburn * current alcohol or substance use judged by the ip to potentially interfere with patient study compliance. * routine administration of steroid based medications. * patients currently taking part in any other clinical trial using an investigational product within the last 3 months
safety and efficacy study of mix vaccine in hepatocyte carcinoma patient

Conditions: Liver Neoplasms

Summary: the purpose of this study is to evaluate the safeness and effectiveness of mix vaccine (mv). enrolled patients will receive standard treatment according to national comprehensive cancer network (nccn) guide line with or without combining mv injection. the efficacy and side effect will be compared between the two groups.

in the study, after evaluation of the general and physical status, eligible patients will be enrolled and randomly assigned into two arms at an 1:1 ratio. in the control arm patients will be receiving standard therapy according to national comprehensive cancer network (nccn) guide line (control group) and in experimental arm, patients will be receiving simultaneous standard therapy and injection of mix vaccine (mv). mv will be injected weekly till disease progression. blood sample will be obtained at baseline and every week before mv injection for the assessment of clinical hematology, biochemistry measurements and immunology index (including immunoglobin, interleukin and interferon). patients will be evaluated for toxicity throughout the study. side effect, progression free survival, immunology index and general status will be recorded.

Eligibility criteria:
inclusion criteria: * patients diagnosed with hepatocyte carcinoma based on histology * evaluable lesions on imaging study * without known immunodeficiency * age \>18 and \<80 years ago exclusion criteria: * patients is unable or unwilling to sign informed consent * any autoimmune disorder, which is currently being treated with prednisone or any other immune suppressive medication * positive hiv and/or rpr (rapid plasma reagin) * female patient who is pregnant or breast feeding * patients, based on the opinion pf the investigator, should not be enrolled into this study * prior anti-cancer vaccine or biological immunotherapy * allergic to any known ingredient of the mv compound

Keywords: mix vaccine, liver neoplasms, immunotherapy